Itonis Pharmaceuticals Completed Evaluation of Emesyl Product to Take Next Step to Manufacturing
March 19 2014 - 11:00AM
Marketwired
Itonis Pharmaceuticals Completed Evaluation of Emesyl Product to
Take Next Step to Manufacturing
LAGUNA HILLS, CA--(Marketwired - Mar 19, 2014) - Itonis, Inc.
(PINKSHEETS: ITNS) is pleased to announce that Charles Hensley,
PhD., the inventor of the Zicam® cold remedy, and his team has
completed their evaluation of the manufactured samples of Emesyl™,
the company's over-the-counter homeopathic product for nausea
relief.
The Company has completed its evaluation of the Emesyl™ samples
received from Oasis Health Products. "We are pleased with the
quality of the product samples and have selected the version for
manufacturing", says Dr. Charles Hensley. "It's important that we
take these steps to insure that consumers will have a product that
is not only effective but easy to tolerate."
About Itonis
Pharmaceuticals Itonis Pharmaceuticals, a division of
Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission
is to create and market over-the-counter and prescription
homeopathic products that better people's lives. Dr. Hensley is a
pioneer in the development and marketing of safe and effective
therapeutic nutraceutical and homeopathic preparations. He was a
founder of the company that launched the Zicam® Cold Remedy, making
the product a household name and forever changing the marketing and
product placement paradigm for homeopathic drugs in the United
States. Dr. Hensley and his team plan to use the same methodologies
to revolutionize the treatment of several other common ailments and
other chronic diseases.
About Itonis,
Inc. Itonis, Inc. was incorporated in the state of Nevada on
July 5, 2005 under the name of Kenshou, Inc., which later changed
to Itonis, Inc. on December 2, 2005. Please visit
www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Contact: Itonis, Inc. Email Contact
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Itonis (PK) (USOTC:ITNS)
Historical Stock Chart
From Apr 2023 to Apr 2024